Quick Answer
Unicycive Therapeutics, Inc. reported Total Revenue of $675.0 thousand for fiscal year 2023.
Unicycive Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2023 | $675.0K | -29.0% |
| 2022 | $951.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $675.0K | — | -29.0% |
| September 30, 2022 | $951.0K | — | — |
- Unicycive Therapeutics, Inc. showed a decrease of -29.0% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2023 period, Unicycive Therapeutics, Inc.’s total revenue has declined by 29.0% (from $951.0 thousand to $675.0 thousand).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: